EN DE
Watch iRhythm Technologies Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

iRhythm Technologies Inc (IRTC) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of iRhythm Technologies Inc stock $16.68, price $88.68, that is 81.2% below the price, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US4500561067

IT iRhythm Technologies Inc logo Thin data Nov 11, 2026

iRhythm Technologies Inc

IRTC · US

Far too expensive (fair value 81% below the price) and falling price, but company just good enough: meets 1 of 3 rules.

Get notified free when this changes
Generates free cash flow 
Recent news very positive 
Quality 47/100 
Mixed Growth (revenue 5y +23.0 %/yr in USD) 
Insiders sold $8.0M (6M) 
Fair value $16.68 · Strongly overvalued 
Falling price (downtrend) 
Loss-making · -4.5% net margin (TTM) 
High debt 
Trails peers (2/12) 
Narrow moat 22/100 · thin data
Thin data 
Extreme value

Main risks:

🚩Patient notifications after June data access incident
Watch iRhythm Technologies Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$189.25 $41.91 Fair Value $16.68 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $41.91 – $189.25 · fair‑value band $5.00 – $38.24 · the $88.68 price screens above the $16.68 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow iRhythm Technologies in your weekly email

Every Wednesday you see whether iRhythm Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States.

Show moreShow less

The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.

It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data.

In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period.

It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services.

The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Stock analysis

iRhythm Technologies Inc (IRTC) currently trades at $88.68, while our model-based Fair Value estimate is $16.68, 81% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $14.85 per share, and 0 of the 6 models we run sit above the $88.68 price.

Bear case: the Asset-Based group reads lowest at $3.07, and 6 of the 6 models stay below the price. Data coverage for this calculation is low.

Scenario range: $5.00 (bear) to $38.24 (bull), the price of $88.68 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

iRhythm Technologies Inc reported revenue of $747M in FY2025 versus $323M in FY2021, a compound +23.3%/yr. Reported net income was −$44.6M in FY2025.

Key figures

Market cap $2.9B Mid · P/S ratio 3.51 · EPS (TTM) $−1.17 · Net margin −4.5% · Return on equity −25.8% · Return on assets (EBIT) −18.4% (5-year average) · Operating margin 10.4% · Revenue (TTM) $854M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 53% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −81%, IRTC screens richer than that median.

Fair Value models

Bear $5.00 Fair Value $16.68 Bull $38.24
Price $88.68 · Downside -81.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $6.18 $14.85 $40.83 70
Growth DCF $5.00 $16.68 $38.24 70
10Y Revenue Exit $2.12 $16.41 $24.58 63
All 7 models by family
DCF Models
FCF DCF $6.18 $14.85 $40.83 70
5Y Revenue Exit $0.5100 $8.73 $25.83 62
10Y Revenue Exit $2.12 $16.41 $24.58 63
Multiples
EV/Revenue n/a n/a $2.66 50
Asset-Based
NCAV (Graham) $2.29 $3.07 $4.58 54
Growth DCF
Growth DCF $5.00 $16.68 $38.24 70
Rev-Margin DCF $1.19 $11.79 $32.81 62

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 30
How much profit the company makes from its sales and capital
Quality Growth 93
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 36
Debt, balance sheet and risk of trouble
Investment 59
Does it invest with discipline instead of growing at any price?
Low Volatility 15
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 55
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 10 officers or directors sold shares worth $8.0M and none bought.

  • SaleDaniel G. WilsonChief Financial Officer3× since Feb 25, 2026: 9,356 shares, avg. $131.77$1.2MSep 2, 2026
  • SaleQuentin S. BlackfordPresident and CEO, Director3× since Feb 25, 2026: 66,212 shares, avg. $129.59$8.6MAug 10, 2026
  • SalePatrick Michael MurphyCBO and CLO4× since Dec 2, 2025: 21,733 shares, avg. $136.14$3.0MAug 10, 2026
  • SaleChad PattersonCHIEF COMM & PRODUCT OFFICER5× since Dec 2, 2025: 23,496 shares, avg. $129.90$3.1MAug 10, 2026
  • SaleSumi ShrishrimalEVP, Chief Risk Officer4× since Feb 25, 2026: 16,135 shares, avg. $127.71$2.1MAug 10, 2026
  • SaleMinang TurakhiaCHIEF MED/SCI OFCR EVP ADVTECH4× since Feb 25, 2026: 20,347 shares, avg. $129.54$2.6MAug 10, 2026
  • SaleMervin SmithEVP Strategic Business Ops5× since Feb 24, 2026: 9,327 shares, avg. $128.11$1.2MAug 3, 2026
  • SaleJulianne RoddaEVP, CHIEF PEOPLE OFFICER2,112 shares at $122.12$257,917Aug 3, 2026
  • SaleSean Clinton FreemanEVP, Strategy & Corp Devt918 shares at $124.71$114,484Jul 2, 2026
  • SaleMarc Wade RosenbaumChief Accounting Officer4× since Feb 24, 2026: 6,622 shares, avg. $131.80$872,750Jun 2, 2026

Plus 3 more entries from the last 12 months.

Plus 18 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+26.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.0%
Start year 2020 (pandemic). Over 10 years: +35.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−16.5% (2020) → −4.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+41.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+18.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +38.5% a year for the price and +15.3% for the forecasts.
Forecast 2026 (sales)+19.6%
Forecast 2027 (sales)+21.4%
Projected 2028 (sales)+19.0%
Projected 2029 (sales)+16.5%
Projected 2030 (sales)+14.1%

IRTC screens overvalued: fair value 81% below the price. Compare with Abbott Laboratories, →

Recent news

News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Oct 11, 2026
AI conclusion: The VitalConnect acquisition widens addressable markets for cardiac monitoring, yet persistent losses and high debt continue to limit business durability.
Main risk: Fallout from the unauthorized data access incident risks eroding patient trust and slowing adoption of the core monitoring services.
iRhythm completed its acquisition of VitalConnect last week, adding mobile cardiac telemetry and multi-vitals monitoring to its existing Zio service and extending reach into inpatient and hospital-to-home settings. The move aims to widen the addressable market and accelerate growth from 2027 onward while the company begins notifying patients impacted by unauthorized access to data in June. Will the broader platform deliver enough new revenue streams to outweigh added integration demands and any fallout from the security incident?
Join the discussion →

Compare iRhythm Technologies Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 404 stocks

Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −81.2% · Bottom 25%
Profitability
Return on assets −4.4% · Below median
Net margin (12 months) −4.5% · Below median
Operating margin (12 months) 10.4% · Above median
Growth and dividend
Revenue growth (quarter YoY) 14.9% · Above median
Balance sheet
Debt / equity 4.25× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 19.10× · Priciest 25%
P/S (12 months) 3.42× · Pricier than median
Price / free cash flow (fiscal year) 84.5× · Priciest 25%
EV/EBITDA 73.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)75 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥177.51 ¥202.57 +14% vs IRTC
Stryker Corporation SYK $318.79 $358.30 +12% vs IRTC
DexCom, Inc DXCM $80.35 $89.18 +11% vs IRTC
STERIS plc STE $256.27 $281.90 +10% vs IRTC
Boston Scientific Corporation BSX $45.13 $48.42 +7% vs IRTC
GE HealthCare Technologies Inc GEHC $82.60 $69.92 −15% vs IRTC
Edwards Lifesciences Corporation EW $105.81 $81.94 −23% vs IRTC
Medtronic plc MDT $101.61 $74.90 −26% vs IRTC
Abbott Laboratories, ABT $109.29 $75.28 −31% vs IRTC
Koninklijke Philips N.V PHIA €27.26 €15.23 −44% vs IRTC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

iRhythm Technologies Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "iRhythm Technologies Inc Fair Value". https://www.fairvalue-calculator.com/stock/IRTC

Frequently asked questions

Is iRhythm Technologies Inc (IRTC) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of $16.68 versus a price of $88.68, about 81% lower (overvalued).
What is the fair value of IRTC?
Our model-based fair value for iRhythm Technologies Inc is $16.68 (as of Nov 11, 2026), built from audited fundamentals. The current price: $88.68.
What is the quality score of IRTC?
iRhythm Technologies Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for iRhythm Technologies Inc (IRTC)?
Our model-based price target is the fair value of $16.68 (as of Nov 11, 2026) from 7 valuation models. Cautious scenario $5.00, optimistic scenario $38.24. It is a calculation from audited fundamentals, not an analyst target.
What is the iRhythm Technologies Inc stock forecast for 2026?
Our models put fair value at $16.68, about 81% lower versus a price of $88.68 (overvalued). Cautious scenario $5.00, optimistic scenario $38.24. The calculation is refreshed regularly with new filings.
What is the revenue of iRhythm Technologies Inc (IRTC)?
iRhythm Technologies Inc reported trailing-twelve-month revenue of about $854M (latest available figure, as of Nov 11, 2026).
What growth is priced into iRhythm Technologies Inc (IRTC)?
For today's price to be fair in a discounted-cash-flow model, iRhythm Technologies Inc would have to grow free cash flow by +41.8 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +23.0 % per year. As of Nov 11, 2026.
What discount rate (WACC) does the fair value of IRTC use?
Our models discount iRhythm Technologies Inc at 10.9 %: a base by market capitalisation (mid), damped by beta 1.47, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For iRhythm Technologies Inc that is +41.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has iRhythm Technologies Inc (IRTC) delivered so far?
Over the past 5 years revenue at iRhythm Technologies Inc grew +23.0 % a year. The price currently implies free-cash-flow growth of +41.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of iRhythm Technologies Inc (IRTC) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into iRhythm Technologies Inc (+41.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of iRhythm Technologies Inc (IRTC)?
The free-cash-flow yield on the price is 1.18 %: that much free cash flow iRhythm Technologies Inc produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of iRhythm Technologies Inc (IRTC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For iRhythm Technologies Inc it is $16.68 per share (as of Nov 11, 2026), against a price of $88.68. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is iRhythm Technologies Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, IRTC trades above its calculated fair value: price $88.68, fair value $16.68, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IRTC?
No. The price is what the market pays today ($88.68); the fair value is what the company's own numbers justify ($16.68). For iRhythm Technologies Inc the two are $72.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is iRhythm Technologies Inc worth?
The market values iRhythm Technologies Inc at about $2.9B (market capitalisation, as of Nov 11, 2026). Per share that is $88.68; our models calculate a fair value of $16.68 per share.
What do the bullish and bearish scenarios say about IRTC?
Our models span a range for iRhythm Technologies Inc: cautious scenario $5.00, base $16.68, optimistic $38.24 per share (as of Nov 11, 2026, price $88.68). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of iRhythm Technologies Inc (IRTC)?
Balance-sheet figures for iRhythm Technologies Inc (as of Nov 11, 2026): return on equity −25.8%, debt of 4.25 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is IRTC from its 52-week high?
iRhythm Technologies Inc trades at $88.68, about 53% below its 52-week high of $189.25 and 3% above the low of $86.06 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $16.68 is for.
Which stocks are comparable to iRhythm Technologies Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is iRhythm Technologies Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $88.68, calculated fair value $16.68 (−81%), Quality Score 47/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IRTC calculated?
We run iRhythm Technologies Inc through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $16.68 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. iRhythm Technologies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of iRhythm Technologies Inc (IRTC)?
The closing price on Nov 11, 2026 was $88.68. Our model-based fair value is $16.68, about 81% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with iRhythm Technologies Inc right now?
The price sits above even our optimistic bull case ($38.24). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($5.00 to $38.24). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of iRhythm Technologies Inc

How large is the market capitalisation of iRhythm Technologies Inc (IRTC)?
The market capitalisation of iRhythm Technologies Inc is $2.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of iRhythm Technologies Inc (IRTC)?
The price-to-sales ratio of iRhythm Technologies Inc is 3.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of iRhythm Technologies Inc (IRTC)?
Earnings per share at iRhythm Technologies Inc are $−1.17. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of iRhythm Technologies Inc (IRTC)?
The net margin of iRhythm Technologies Inc is −4.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of iRhythm Technologies Inc (IRTC)?
The return on equity (ROE) of iRhythm Technologies Inc is −25.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of iRhythm Technologies Inc (IRTC)?
On an EBIT basis the return on assets of iRhythm Technologies Inc is −18.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of iRhythm Technologies Inc (IRTC)?
The operating margin of iRhythm Technologies Inc is 10.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at iRhythm Technologies Inc (IRTC)?
Revenue at iRhythm Technologies Inc is growing +14.9% versus a year earlier (3y avg +22.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does iRhythm Technologies Inc (IRTC) carry?
The net debt of iRhythm Technologies Inc is $495M (fiscal year 2025, ≈ 14.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch iRhythm Technologies Inc in the live analysis

One click puts iRhythm Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.